CMS Releases List of Drugs for Medicare Price Negotiation
The Centers for Medicare and Medicaid Services (CMS) has released the list of the first 10 drugs to be negotiated under the Inflation...
top of page
Subscriber login:
SUBMIT
Remember me
Search
- Aug 1
Using Technology to Transform Specialty Medication Access and Affordability
We need a streamlined approach where stakeholders can perform all critical tasks — from enrollment and patient consent to prior...
- Mar 24
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne...
- Feb 14
Exclusive: Profiling Manufacturers’ Limited and Exclusive Pharmacy Networks for Specialty Drugs
A deep dive into the relationships between manufacturers of specialty drugs and the pharmacies they choose for their limited and...
- Oct 14, 2022
How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022
Julie Kendle, Director, Clinical Pharmacy Director, Clinical Pharmacy at IPD Analytics addresses tips on improving accumulators and ways...
- Aug 23, 2022
High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023
The FDA approved the first high-concentration adalimumab biosimilar. A low-concentration version of the biosimilar, Hadlima, was already...
- Jul 21, 2022
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars
The budget allocates half of the money for the development of low-cost interchangeable insulin biosimilars and the other half for...
- Jul 16, 2022
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug
ICER's expert group unanimously voted against Biogen's Aduhelm and its benefit for Alzheimer's patients. (Biogen) By Noah Higgins-Dunn |...
- Jun 22, 2022
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, discussed the different options that payers have to manage the growing...
- Jun 1, 2022
6 Payor Tactics to Control Drug Spending
Kimberly Grant, PharmD, and Julia Mahler, PharmD, clinical pharmacists with IPD Analytics, state that specialty products are outpacing...
- Jun 1, 2022
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations
Research presented at EULAR 2022 demonstrated the pharmacokinetic equivalence of a low-concentration version of the adalimumab biosimilar...
- May 30, 2022
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says
With multiple adalimumab biosimilars poised to enter the market and more biosimilars in more disease states seeking interchangeability,...
- May 26, 2022
Payer Management Tools and Trends for Biosimilars in the US
As biosimilar competition heats up in the United States, payers have more tools at their disposal to manage these agents. By Laura Joszt...
- Apr 12, 2022
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, weighs in on the factors he thinks will most affect market share among...
- Apr 1, 2022
Upcoming Generics Provide New Considerations and Opportunities for Savings
In 2022 and 2023, there are a number of big therapies losing patent exclusivity, which opens the door to generics that could save as much...
- Mar 29, 2022
Jeffery Casberg Previews His Presentations at AMCP 2022
Jeffrey Casberg, vice president of pharmacy at IPD Analytics, previews his sessions about the new and emerging pharmaceutical products...
- Mar 25, 2022
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022
The annual spring meeting of AMCP 2022 will include keynote sessions on health care and marketplace trends and the specialty...
- Nov 18, 2021
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options
An ICER review of eculizumab and efgartigimod for Myasthenia Gravis expressed serious concerns about drug pricing.
- Nov 1, 2021
IPD Executive Offers Perspective on Biosimilar Uptake and Policy
Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to robust savings in recent years.
- Nov 1, 2021
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve
Authorized biologics are on the horizon and their release will likely coincide with the arrival of the first interchangeable biosimilar.
bottom of page